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Hepatitis-C (HCV) infection can induce kidney injury, mostly due to formation of immune-
complexes and cryoglobulins, and possibly to a direct cytopathic effect. It may cause acute kid-
ney injury (AKI) as a part of systemic vasculitis, and augments the risk of AKI due to other
etiologies. It is responsible for mesangiocapillary or membranous glomerulonephritis, and accel-
erates the progression of chronic kidney disease due to other causes. HCV infection increases
cardiovascular and liver-related mortality in patients on regular dialysis. HCV-infected patients
are at increased risk of acute post-transplant complications. Long-term graft survival is com-
promised by recurrent or de novo glomerulonephritis, or chronic transplant glomerulopathy.
Patient survival is challenged by increased incidence of diabetes, sepsis, post-transplant lympho-
proliferative disease, and liver failure. Effective and safe directly acting antiviral agents (DAAs)
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Renal transplantation
Direct-acting antiviralsare currently available for treatment at different stages of kidney disease. However, the relative
shortage of DAAs in countries where HCV is highly endemic imposes a need for treatment-
prioritization, for which a scoring system is proposed in this review. It is concluded that the
thoughtful use of DAAs, will result in a significant change in the epidemiology and clinical pro-
files of kidney disease, as well as improvement of dialysis and transplant outcomes, in endemic
areas.
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The kidney is an important component of the HCV clinical
syndrome, besides the liver, the musculoskeletal, immune
and hematopoietic systems and the skin. This notorious viral
infection imposes itself as a cause of kidney disease, a major
risk in dialysis wards, and a significant threat in renal trans-
plantation. Fortunately, we are close to bringing it down to
its knees, thanks to the discovery of directly acting drugs
(DAAs), which will soon send this review, and many on the
same topic, to the archives of medical history!
HCV as a cause of kidney disease
HCV can cause kidney disease in four ways: (a) glomerular
immune complex deposition; (b) direct viral invasion of the
renal parenchyma; (c) renal complications of its extrarenal
(e.g. hepatic) manifestations; and (d) nephrotoxicity of drugs
used for its treatment. These mechanisms often interact in
the pathogenesis of several acute and chronic clinical renal
syndromes.
Acute kidney disease (AKD)
HCV can cause acute kidney disease, which often progresses to
acute kidney injury (AKI), in patients with acute or fulminant
cryoglobulinemic vasculitis. Chronic HCV infection, per se,
can be a significant risk factor for AKI in patients with dehy-
dration, sepsis, or advanced liver injury. Finally, AKI is a
potential risk in several HCV treatment protocols.
Cryoglobulinemic vasculitis
This is a systemic disease reported in <5% [1]–15% [2] of
HCV-infected (HCV +ve) patients. It is rarely associated with
‘‘occult” HCV infection that can be only unveiled by nucleic
acid testing in liver or bone marrow biopsy [3]. It is character-
ized by multi-organ involvement, mainly affecting the lungs
and kidneys, skin, musculoskeletal system and peripheral
nerves. The fundamental lesion is endothelial injury, small ves-
sel necrosis, perivascular inflammation with lymphocytic andneutrophilic infiltration and luminal occlusion by cryoglobu-
lins and fibrin thrombi.
In the kidneys, this leads to focal fibrinoid necrosis of the
glomerular tufts, often with crescent formation (Fig. 1). The
renal tubules are affected by ischemic and inflammatory
lesions and contain hyaline and blood casts. The interstitium
is edematous and infiltrated with inflammatory cells. The ure-
teric and bladder mucosa may display vasculitic purpuric
lesions.
The mechanism of vascular injury is typically attributed to
C1q, the active complement component incorporated within
the cryoglobulin complex (Fig. 2). This leads to endothelial
injury by dual effects, namely, (a) activation of the comple-
ment cascade via the classical pathway; and (b) binding to
endothelial complement receptors thereby localizing the injury
in target capillary beds. Complement activation generates
chemotactic factors, C3a and C5a, which recruit and activate
pro-inflammatory leucocytes. It also leads to the formation
of C5-9, the Membrane Attack Complex that may have an
important role in endothelial damage.
In addition, a direct viral cytopathic effect has been pro-
posed to participate in the pathogenesis of endothelial injury
[5] on the basis of observations in human hepatic sinusoids
and umbilical cord [6].
The clinical presentation ranges from isolated hematuria to
acute kidney injury (AKI), sometimes associated with throm-
botic microangiopathy (Fig. 3). If left untreated, the prognosis
becomes extremely gloomy with regards to renal, as well as
patient survival. On the other hand, successful treatment
may lead to complete or partial recovery, unless the damage
has already been extensive, leading to healing with focal or glo-
bal sclerosis.
Non-cryoglobulinemic AKI
Compared to the general population, HCV-infected patients
are at many-fold risk of developing AKI of diverse, apparently
unrelated etiology. In an observational, community-based
study of 648 subjects with chronic HCV infection, as many
Fig. 2 Cryoglobulin. Anti-viral core-protein IgG antibodies
provoke an IgM-rheumatoid factor antibody response, which fixes
and activates complement through the classical pathway [4]. C1q
binding to its receptor on the endothelial cells localizes the
immune complexes to target tissues such as skin, lung, nerve and
kidney. C1q propagates the complement cascade leading to
formation of C4b C2b complex, which is a C3 convertase. C3 is
thus split into C3a and C3b, the latter being a C5 convertase that
splits C5 into C5a and C5b. C3a and C5a are chemotactic; they
recruit neutrophils and trigger an inflammatory response. C5b
interacts with C6-C9 to form C5-9 (Membrane Attack Complex
[MAC]) which, besides the inflammatory process, may be directly
involved in endothelial injury.
Fig. 3 Blood smear in a patient with cryoglobulinemic vasculitis
and thrombotic microangiopathy. Note the red cell fragmentation
with microcytes (M) and schistocytes (S).
116 R.S. Barsoum et al.as 63 patients (9.7%) experienced 124 episodes of AKD events
over a period of follow-up ranging from 3 months to 6 years
[7]. According to Risk-Injury-Failure-Loss of function-
Endstage (RIFLE) criteria, there were 58 (46.8%) at risk, 20
(16.1%) injury, 44 (35.5%) and failure, 2 (1.6%). AKI was
most frequently attributed to hypovolemia associated with
excessive vomiting or diarrhea. The second common causewas bacterial infection in the lungs, urinary or gastrointestinal
tract. 7.3% of patients had advanced cirrhosis, and developed
AKI following an episode of hematemesis, presumably due to
ischemic acute tubular necrosis. 6.5% were associated with
hepatic encephalopathy including the hepatorenal syndrome.
Decompensated liver disease, history of intravenous drug
abuse, diabetes mellitus and high baseline serum creatinine
were independent predictors of developing AKI. End-Stage
Kidney Disease (ESKD) eventually developed in 17.5% of
patients who developed AKI, compared to 1% of those who
did not. Risk factors for ESKD were pre- existing diabetes,
hypertension or CKD [7].
Treatment-induced AKI
AKI has been infrequently reported with interferon treatment
in patients with cryoglobulinemic vasculitis [8], either by
inducing a flare, or the induction of acute allergic intestinal
nephritis [9]. The latter usually responded promptly to
corticosteroids.
Kidney injury has not been attributed to any of the DAAs.
However, the real-life HCV-TARGET observational study
[10] has reported acute deterioration of kidney function with
Sofosbuvir-based treatment protocols in 5/17 patients (29%)
with eGFR <30 mL/min/1.73 sqm, 6/56 patients (11%) with
eGFR 30–45 mL/min/1.73 sqm, compared to 14/1559 patients
(<1%) with eGFR> 60 mL/min/1.73 sqm. We are currently
investigating a few sporadic cases of acute glomerular injury
during, or immediately following Sofosbuvir treatment,
though the link has not been established yet (unpublished
data).
Chronic kidney disease
HCV-associated chronic kidney disease may be attributed to
cryoglobulinemia, viral antigen-antibody complexes and possi-
bly a direct viral cytopathic effect.
Cryoglobulinemic glomerulonephritis
HCV infection accounts for over 90% of cases with Type II
mixed essential cryoglobulinemia. The latter builds up over
years of active infection, at an increment of about 3% per year
[11]. The average reported incidence is 40–50% [12], with con-
siderable variation in different cohorts. This is partly attribu-
ted to the duration effect, as well as to geographic and
genetic factors.
About 30% of affected patients ultimately develop mesan-
giocapillary glomerulonephritis. Cryoglobulins precipitate in
the glomerular mesangium during their ‘‘macromolecular traf-
ficking” owing to the affinity of the IgM kappa Rheumatoid
Factor (j-RF) to cellular fibronectin present in the mesangial
matrix [13]. By virtue of their integral complement component,
they attach to complement receptors and initiate a mesangial
inflammation. Complement also activates the glomerular
endothelium, which adheres to the circulating cryoglobulins
that deposit in the capillaries providing the main histological
diagnostic clue (Figs. 2 and 4). Endothelial injury includes
the peritubular capillaries leading to an interstitial inflamma-
tory response, which eventually leads to fibrosis and largely
accounts for impaired function.
Hepatitis C and kidney disease 117An interesting scenario has been described in patients with
concomitant infection with Schistosoma mansoni and HCV,
both being frequently endemic in the same geographical
regions, e.g. Egypt. The glomerular lesions are characterized
by a combination of mesangial expansion, amyloid deposits,
and capillary cryoglobulin and fibrin deposits (Fig. 5). The
amyloid component is the hallmark of this co-infection, being
attributed to an imbalance in between the release and the re-
uptake of AA protein by the macrophages. AA is a chemoat-
tractant that is released as a part of the innate immune
response to infection. Its biological half-life is checked by rapid
re-uptake by the macrophages. The latter function is known to
be downregulated by late-phase parasitic antigens as well as
viral core proteins, hence the progressive accumulation of cir-
culating AA protein, and subsequent deposition in inflamed
tissues [14].
The clinical presentation of cryoglobulinemic glomeru-
lonephritis is a combination of the Meltzer triad (comprising
skin vasculitis, arthralgia and myalgia) along with manifesta-
tions of chronic kidney disease. The latter vary from asymp-
tomatic hematuria and/or proteinuria at one end of the
spectrum, to progressive renal failure on the other. Nephrotic
syndrome occurs in one-fifth of cases and nephritic syndrome
in one-sixth. Hypertension occurs in about 70% of patients.
The diagnosis is established by associated Complement-4 (C4)
consumption and strong serum rheumatoid factor (RF) reactiv-
ity, and confirmed by the detection of circulating cryoglobulins,
andHCV by a polymerase chain reaction (PCRc). It is notewor-
thy that there is no correlation in between the extent of renal dis-
ease and severity of hepatic involvement. In a long-term follow-
up study of 231 cases, the 10-year survival in patients with cryo-
globulinemic glomerulonephritis was 62.1% [12].
Non-cryoglobulinemic Immune-complex-mediated
glomerulonephritis
Mesangiocapillary glomerulonephritis may be associated with
HCV infection despite the absence of circulating cryoglobu-Fig. 4 Type I MCGN in HCV-associated cryoglobulinemia. (a) H&E
expansion with extrinsic inflammatory cellular infiltration; (b) Imm
capillary walls; c) Electron microphotograph showing dense subendoth
From Barsoum [5] with permission.lins, in which case HCV-IgG immune complexes are responsi-
ble for the glomerular pathology (Fig. 6). Viral non-structural
protein-3 (NS3) was detected in the glomerular deposits which
were linear or granular along the capillary walls and in the
mesangium [15].
Membranous nephropathy (Fig. 7a) has been associated
with HCV infection on statistical [16] and immunological [17]
grounds. HCV core RNAwas detected in the glomerular depos-
its, suggestive of antigen plantation in the basement membrane.
IgA nephropathy and Focal Segmental sclerosis (Fig. 7b) have
also been associated withHCV infection [16], yet the evidence of
a direct causal relationship remains controversial.
Viral cytopathic effects
HCV antigen may be demonstrated in the glomeruli without
detectable antibodies by enzyme-linked immune-sorbent assay
(ELISA), or viral replication in peripheral blood by conven-
tional PCRc. This may be partly attributed to relative insensi-
tivity of the commonly available techniques [18]. However, it
may also suggest an alternative pathogenic mechanism involv-
ing direct viral glomerular cytotoxicity [5] in analogy with the
occurrence of polyarteritis nodosa in HBV infection without
detectable immune complex deposition [19].
It is possible to speculate that the direct endothelial cyto-
pathic effect [5,6] may explain the accelerated atherosclerosis
observed in HCV-infected patients [20]. The latter has been
partly blamed for the relatively fast progression of CKD in
HCV +ve patients, regardless of the etiology [21].
Dialysis-related HCV infection
HCV infection is widely spread in dialysis units where hygienic
measures are suboptimal. In certain units, the prevalence of
infection exceeds 80% [22]. Not only does this negatively
impact on patient survival [23], and subsequent transplant out-
comes [24], but it also generates a reservoir that disseminates
infection to the community.stain showing capillary cryoglobulin thrombi (arrow), mesangial
unofluorescence showing IgM deposition along the glomerular
elial cryoglobulin deposits with typical finger-printing appearance.
Fig. 5 Cryoglobulinemic mesangiocapillary glomerulonephritis associated with schistosomiasis. (a) Masson trichrome stain showing
typical HCV-cryoglobulinemic deposits, mesangial expansion and amyloid deposits (Class VI Schistosomal glomerulopathy [14]); (b)
Electron microscopy showing randomly deposited amyloid fibrils. From Barsoum [14] with permission.
Fig. 6 Non-cryoglobulinemic HCV-associated mesangiocapillary glomerulonephritis. (a) Light microscopic appearance of typical
glomerular lobulation with mesangial expansion; (b) Electron microphotograph showing granular subendothelial immune complex
deposits. From Barsoum [5] with permission.
118 R.S. Barsoum et al.HCV does not cross the dialysis membranes, so infection
is invariably caused by inter-patient transmission, usually
by the staff. Accordingly, transmission can be prevented by
adequate staff training on universal dialysis wards hygiene
rather than isolating infected patients. However, local regula-
tions in certain countries impose isolation, which has been
rewarded by significant reduction in transmission, expressedas a decline in the sero-conversion of HCV negative patients
[25].
Increased mortality of HCV-infected patients on regular
dialysis (Fig. 8) is mainly attributed to cardiovascular events,
which reflect the chronic endothelial damage induced by the
virus [6,20]. Sepsis and liver failure also contributes to the
decline in patient survival.
Fig. 7 Infrequent glomerular lesions associated with chronic HCV infection. (a) Membranous nephropathy; (b) Focal-segmental
sclerosis (collapsing type in this case). From Barsoum [5] with permission.
Fig. 8 Impact of HCV infection on survival on regular
hemodialysis. From Espinosa et al. [23] with permission.
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Donors
The prevalence of HCV infection among potential donors is
expected to mirror that in the general population, with a global
average of 3% [26]. This number is much higher in developing
countries; it goes up to 15% in Egypt, which has the highest
prevalence in the world. Owing to the risk of transmission with
the graft, there is a general agreement that such donors are
unsuitable for HCV non-infected (HCV ve) recipients.
There is controversy regarding the risk of transmission to
HCV +ve recipients. Since the immune response to the virus
is strain-specific, at least in Chimpanzees [27], viral genotype
discrepancy in between the donor and recipient constitutes a
risk of superinfection, which has actually been observed in tha-
lassemic children [28].
The same risk may be, at least theoretically, extrapolated
even within the same viral genotype, owing to differences in
subtypes [29] or quasispecies [30]. Owing to prolonged pressure
of the immune response over many years of active infection,
the virus typically undergoes limited mutations within the
same genotype, yielding different strains that can co-exist
within the same person. Transplanting an organ carrying such
strains almost certainly exposes the recipient to a new infection
to which he/she may not have an adequate immunological
memory.
Available data seem to suggest a real risk in real-life chal-
lenges to these concerns [31]. In the Organ Procurement and
Transplantation Network (OPTN) database (2001–2006),
6.25% of cadaver kidneys and 2.97% of living-donor kidneys
were obtained from HCV-infected subjects. The outcomes
were significantly inferior regarding both patient and graft sur-
vival [32]. In a large study including 2169 transplants, the rel-
ative risk of death in HCV +ve patients (R+) receiving HCV
+ve donor (D+) kidneys was 2.1 when compared to R-/D-controls. Graft loss in the same study was also increased, yet
it was related to the recipient’s HCV infection per se, regard-
less of the donor’s status [33].
The debate continues despite these limitations, since HCV
+ve patient survival, in almost all relevant reports, was still
significantly superior to that on dialysis [34] (Fig. 9). This
seems to justify taking the risk of receiving a D+ graft rather
than waiting for years on dialysis. Furthermore, the policy of
using D+ kidneys avoids wasting a lot of organs that would
have saved many lives [35].
Recipients
Potential transplant recipients have a much higher prevalence
of HCV infection than that in the general population, ranging
all the way from 3% to 80% in different countries. This reflects
Fig. 9 Five-year comparative relative risk of death of HCV +ve
patients on hemodialysis versus kidney transplantation. Based on
data from Pereira et al. [37].
120 R.S. Barsoum et al.the frequency of exposure to contaminated dialysis, transfu-
sions, interventions, etc. The main infection-related factors
that determine eligibility to transplantation depend on the
extent of liver damage, extrarenal morbidity, and the presence
of cryoglobulinemia [36].
Active HCV infection carries a significant risk to patient as
well as graft survival. The main adverse events are encountered
either during the first 3 months or over 10 years post-
transplant (Fig. 9) [37].
Early events
There is a significantly increased risk of acute transplant
glomerulopathy (RR 6.8–8.8) and acute vascular rejection
(RR 2.2) in HCV +ve recipients (Fig. 10)[38]. Either compli-
cation may be associated with thrombotic microangiopathy
[39], usually in the presence of a thrombophilic environment.
The latter includes congenital or acquired deficiency of coagu-
lation inhibitors, anticardiolipin antibodies, or the use of high
doses of calcineurine or mTOR inhibitors.
There is no agreement on the risk of acute cellular rejection,
the RR of which was reported to vary from 0.9 to 1.3 [40].Fig. 10 Early post-transplant complications in HCV +ve recipients.
transplant glomerulopathy. From Barsoum [5] with permission.Late complications
In a metanalysis of 6365 unique HCV+ve patients included in
8 clinical trials, the long-term patient- and graft survival were
compromised (RR 1.79 and 1.56 respectively) [41]. All-cause
mortality was increased, mainly due to liver or cardiovascular
disease [24]. Graft loss was mainly attributed to de novo or
recurrent glomerulonephritis, and to increased incidence of
chronic transplant glomerulopathy [33].
In that analysis and other cohorts, the main complications
reported in HCV +ve recipients were infection, post-
transplant diabetes (NODAT) or lymphoproliferative disor-
ders (PTLD), glomerulonephritis, cryoglobulinemic vasculitis
and hepatocellular failure.
Infection
Infection is decidedly the second common cause of death
among kidney transplant recipients at large [42]. There is con-
troversy whether HCV +ve recipients are at a higher risk of
infection-related mortality. While it was so in a small Indian
cohort [43], this effect was not substantiated by USRDS data
[42], nor in a large Spanish study including 4304 renal trans-
plant recipients [44]. However, another Spanish study includ-
ing 1302 kidney transplant recipients showed that while there
was no difference in the overall incidence of infection in
between HCV +ve and HCV ve recipients, bacteremia and
upper urinary infection were significantly more common in
the former [45].
Diabetes
The reported incidence of new-onset diabetes after transplanta-
tion (NODAT) is variable owing to difference in the diagnosis,
time from transplant, study population, and immunosuppres-
sive agents used. Adopting the definitions of the American Dia-
betes Association (ADA) [46], and the International Consensus
Guidelines on NODAT [47], Vincenti et al. reported an inci-
dence of 20.5% within the first 6 months post-renal transplan-
tation [48].(a) Acute cellular rejection; (b) Acute vascular rejection; (c) acute
Hepatitis C and kidney disease 121In a retrospective analysis of 555 kidney transplants, hep-
atitis C virus (HCV) infection was an independent risk factor
for post-transplant diabetes. It had a negative impact on both
patient and graft survival, irrespective of the time of onset and
duration of diabetes [49]. A meta-analysis of 10 studies includ-
ing 2502 patients showed that HCV +ve patients were nearly
four times more likely to develop NODAT, compared with
uninfected individuals [41]. Impaired Insulin sensitivity [50]
and direct viral damage on pancreatic b cells were the pro-
posed underlying mechanisms [51].
Post-transplant lymphoproliferative disease (PTLD)
The overall cumulative incidence of PTLD in kidney trans-
plant is about 1.18% after 5 years [52], with mortality rates
exceeding 50% [53]. A direct effect of HCV infection on the
carcinogenesis of lymphoid cells has been well documented
[54]. HCV +ve patients with native kidneys have a 1.26-fold
increased risk of non-Hodgkin lymphoma (NHL), compared
to the general population [55]. In occasional case reports, even
Hodgkin lymphoma was controlled following antiviral treat-
ment of HCV infection [56].
The potential risk PTLD in HCV +ve transplant recipients
is controversial, since an intact immune system is believed to
be a prerequisite for sustained B-lymphocyte proliferation
[57]. Clinical data are inconsistent, showing both positive
[58] and neutral [57] impacts of HCV infection. However,
PTLD was reported to regress upon reduction of immunosup-
pression and successful control of HCV viremia [59].
Glomerulonephritis
Proteinuria
In a single-center retrospective study of 322 renal transplant
recipients, positive pre-transplant serology for anti-HCV anti-
bodies (9.6% of patients) was an independent risk (RR 5.36)
for the development of significant (>1 g/24 h) proteinuria
[60]. De-novo glomerular lesions were detected in 26/44 biop-
sies obtained from these patients. This difference was not
observed in a long-term (87.73 ± 26.79 months) follow-up of
273 patients of whom 169 had anti-HCV antibodies [61]. A
third study of 335 recipients showed that while mild protein-
uria (<300 mg/day) occurred at a comparable frequency in
HCV +ve and HCV ve patients, moderate and severe pro-
teinuria was significantly more common in HCV +ve patients
(48.2% vs. 29.4% respectively) [62].
It is conceivable that post-transplant proteinuria is not a
single entity. It can be a marker of rejection, drug toxicity,
recurrence or de novo glomerulonephritis, etc. The impact of
HCV in the pathogenesis of these conditions is quite variable,
hence the differences in between different cohorts.
Recurrence of glomerulonephritis
HCV-associated MPGN and MGN are known to recur after
transplantation [63]. In different reports, the incidence of
recurrence ranged from 20% to 30% for MPGN and 3% to
7% for MGN [64]. Recurrence usually occured after the sec-
ond year. Most cases were non-cryoglobulinemic. Otherwise,
the clinical, laboratory and histopathological features were
similar to those with native kidney disease.De-novo glomerulonephritis
HCV seropositivity is a significant risk factor in the develop-
ment of de novo glomerulonephritis. In one study, 63% of
diagnostic renal allograft biopsies in HCV +ve recipients
showed pathologic findings of de novo GN (45% MPGN
and 18% MGN), compared to 5.8% and 7.7% respectively
in HCV ve patients [65]. Similar observations were reported
in other cohorts [66,67]. De-novo FSGS has also been reported
in HCV +ve patients, yet with a similar frequency to that in
HCV ve patients [68]. It has been attributed to other factors
as glomerular ischemia, drug effect, etc. However, the poten-
tial of an independent direct podocyte cytopathic effect of
HCV cannot be excluded in HCV +ve patients [5].
 De-novo membranoproliferative glomerulonephritis.
De-novo MPGN usually occurs during the first year post-
transplant. Yet it has also been reported as late as 10 years
[69]. Cryoglobulins are seldom detected, presumably as a result
of immunosuppression. However, serum complement C4 is
usually low [36], denoting consumption in the process of
immune complex deposition. The clinical, laboratory and
histopathological features are similar to those associated with
the primary disease in native kidneys. The pathogenic role of
HCV infection is confirmed by the detection of antibodies in
the glomerular deposits [9] and the response to antiviral treat-
ment [70].
 De-novo membranous nephropathy.
The reported incidence of de novo membranous nephropa-
thy in HCV positive recipients is almost double that in HCV
ve recipients. It is usually diagnosed 2 years after transplan-
tation. The clinical features are similar to the primary disease.
Compared to the latter, anti-phospholipase A2 antibodies were
not detected in most reported cases [71], and the course was
more rapidly progressive, leading to graft failure in an average
of 2 years [72]. These features suggest a different pathogenic
mechanism, which may be related to a direct cytopathic effect
of HCV on the podocytes [5].
Chronic liver disease (CLD)
HCV infection is the leading cause of CLD after kidney trans-
plantation and is associated with increased long-term mortality
[73]. In a follow-up of 42 HCV +ve recipients for a mean of
7.6 years, after transplantation, 45.2% displayed aggressive
hepatitis progression. Patients who acquired HCV infection
peri- or post-transplantation had an increased risk of hepatitis
progression compared with those infected before transplanta-
tion [74].
The deleterious effect on hepatic pathology is generally
attributed to immunosuppression. HCV viremia is consistently
increased many folds after transplantation, even in those who
had achieved a sustained viral response under interferon/rib-
avirin treatment [75]. The outcome of treatment with DAAs
in this respect awaits further experience.
Ironically, the increased viral load under immunosuppres-
sion does not seem to correlate with short-term hepatic injury.
In a cohort of 36 renal transplant recipients who have been
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liver fibrosis while 23 did not, as assessed by 2 liver biopsies
obtained 45 and 81 months after transplantation. There were
no significant differences in the increases in serum HCV
RNA or genotype distributions in ‘‘fibrosers” and ‘‘nonfi-
brosers” [76]. So, it seems that the altered response to infec-
tion, rather than an increase in its load, is what explains the
deleterious effect of immunosuppression.
There is no consistent advantage of a particular immuno-
suppressive agent over another with regard to progression of
hepatic fibrosis. In a large study involving 3708 HCV+ve kid-
ney transplant recipients, neither antibody induction nor the
use of corticosteroids had an effect on patient survival [77].
The use of mycophenolate mofetil was associated with both
better [22] and worse [78] patient survival.
There is a theoretical advantage of cyclosporine, since it
binds to cyclophylline, which is involved in viral replication
[79]. However, this was not confirmed in clinical studies, that
have shown no significant difference in viral replication or pro-
gression of liver fibrosis with the use of cyclosporine compared
to tacrolimus [80].
Fibrosing cholestatic hepatitis (FCH)
This is a rare, severe form of liver disease characterized by
cholestasis, progressive hepatic failure and death if liver trans-
plantation is not performed. It was reported in four (1.5%) of
259 HCV-infected renal transplant recipients by the end of the
first year. Liver biopsy revealed diffuse fibrosis, leukocyte infil-
trates, and different degrees of cholestasis. Two patients devel-
oped subfulminant liver failure and died 2 and 3 months after
biopsy, one was saved by a liver transplant, and the fourth was
treated with interferon, rejected his graft and returned to dial-
ysis [81].
Management
With the aforementioned renal impact of HCV infection, there
is a strong rationale of getting rid of the virus at all stages of
CKD [35]. Unfortunately, there are no prospective random-
ized trials that document the ultimate effect of treatment on
renal or patient survival. The available data are obtained from
small cohorts, treated with the old interferon/ribavirin proto-
cols. Metanalysis of these studies has displayed conflicting
results, which may be attributed to heterogeneity of patient
demographics, stage and nature of kidney disease, extent of
liver injury and associated extrarenal manifestations, e.g.
cryoglobulinemia.
In a metanalysis of 11 studies comprising 107 patients trea-
ted with interferon with or without ribavirin, proteinuria
regressed to a variable extent in those who achieved end-of-
treatment viral response. A few patients relapsed when the
viral clearance was un-sustained. There was no significant
change in serum creatinine in all studies except 2, where the
GFR was increased. No post-treatment biopsy was reported
[20].
In a metanalysis of 24 prospective studies, including 529
HCV +ve patients on hemodialysis who were treated with
interferon-alpha (IFN-a) it was shown that monotherapy
resulted in a sustained viral response at 48 weeks (SVR48) in
only 39% of cases [82]. Better outcomes (SVR48 of 50–60%)were achieved by a combination of Peg-interferon and reduced
doses of ribavirin [83]. Survival was significantly improved in
treatment responders, with a hazard ratio for death of 0.47
compared to untreated patients according to the DOPPs data
including 4589 HCV-infected patients [84]. Despite this
remarkable advantage, only 1% of patients on regular dialysis,
and 3.7% of those on the transplant waiting list actually
received treatment during the Interferon era [84]. This trend
will undoubtedly change with the introduction of DAAs,
which currently achieve a SVR12 of 100% with Paritaprevir/
Ritonavir + Ombitasvir [85] or 84.6% with RBV-free
Simeprevir + 1/2 dose sofosbuvir [86].
Considering the obvious independent risk of HCV infection
in kidney transplant recipients, it is logical to treat all patients
prior to transplantation. However, there is no randomized
prospective trial to prove that the risk of HCV infection is
totally eliminated by pre- transplant viral clearance. In other
words, there is no evidence that previous chronic HCV infec-
tion has no long-term legacy that would still have a negative
impact on patient and graft survival.
In addition to their remarkable efficacy and safety profiles,
DAAs offer 2 major advantages in patients with CKD, namely
a favorable pharmacokinetic profile and the lack of any
immune-stimulatory effect.
DAAs are mainly metabolized in the liver. With a few
exceptions, they are not retained in renal failure to any clini-
cally significant extent. By way of contrast, 90% of an admin-
istered dose of interferon [87] and 61% of ribavirin [88] are
excreted in urine. Accordingly, their adverse reactions are aug-
mented in patients with low GFR, including the ribavirin-
induced hemolytic anemia and the long list of interferon side
effects [89], mostly the hematopoietic.
The immune stimulatory effect of interferon therapy is a
serious threat of aggravating cryoglobulinemic syndromes
[90], inducing AKI due to acute interstitial nephritis [9], and
rejecting kidney transplants [91]. None of this occurs with
DAAs, which extends the spectrum of their use to previously
forbidden horizons.
Treatment prioritization
Despite the anticipated benefit in patients with kidney disease,
the overwhelming demand imposes the necessity of prioritizing
those at highest risk of death or serious morbidity. A scoring
system was put together for stratifying patients accordingly,
which is currently adopted by the Egyptian Ministry of Health
(Table 1) [92].
Choice of treatment protocol
The choice of a treatment protocol out of the plethora of avail-
able DAAs (Table 2) depends on many factors. Before
embarking on a particular protocol, confounding factors must
be taken into consideration, including the extent of liver dam-
age, viral genotype, previous treatment, co-morbid conditions,
and concomitant regular drug administration [92].
Liver disease
Evaluation of the extent of liver disease is essential for safe and
effective DAA prescription to a patient with kidney disease,
Table 1 Proposed CKD prioritization scheme for HCV treatment. From El-Fishawi et al. [92] with permission. Each patient shall be
scored by adding up points in favor of treatment and subtracting points that would lower his/her priority either due to lower
opportunity to benefit from treatment or lack of urgency.
Positive points:
Post-renal transplant 5 points
Regular Dialysis 5 points
Biopsy confirmed MCGN with hypocomplementemia 4 points
Biopsy-confirmed MCGN without hypocomplementemia 3 points
Nephrotic syndrome 2 points
Previous treatment failure 2 points
HBV/HIV/ CMV co-infection 2 points
Cryoglobulinemic vasculitis 2 points/AASLD stage
Stage of kidney disease (MDRD-4) 1 point/stage
Stage of liver disease (Fibroscan) 1 point/stage
Negative points:
Age > 50 1 point/5 years
Decompensated cirrhosis 5 points
Concurrent drug-drug interaction with selected Protocol 5 points
Concomitant heart disease 1 point/NYHA score
Concomitant pulmonary disease 1 point/10% FVC1
Concomitant CNS disease 1 point/10% disability
The threshold for accepting patients for treatment shall vary according to availability.
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rhosis permits the use of an interferon-free and ribavirin-free
protocol for 12 weeks, expecting over 90% sustained viral
response at 12 weeks (SVR12). The latter is accepted by the
FDA as a 99% predictor of complete cure [93]. The presence
of cirrhosis (Fibrosis score >3 by transient elastography –
‘‘Fibroscan”) requires the inclusion of ribavirin in most proto-
cols. If ribavirin is contraindicated or not tolerated, DAA
combination treatment must be extended for 24 weeks. Hepa-
tocellular decompensation constitutes a significant challenge
for the choice of safe antiviral treatment. Of the currently
available DAAs, Daclatasvir-based therapy seems to be partic-
ularly safe and effective [94], while the Viekera family is con-
traindicated owing to its association with death or severe
morbidity [95].
Genotype
The viral genotype is an important determinant of response to
treatment. The choice of treatment protocol must be based on
genotype-specific randomized controlled trials (RCTs)
(Table 2). Since HCV genotypes are globally dispersed on geo-
graphical basis, it is presumed that patients in the same com-
munity share the same genotype, which justifies the adoption
of country-specific guidelines. Whenever there is paucity of
RCTs on a particular genotype, it makes sense to extrapolate
data on pangenotypic drugs from other genotype studies [92].
Previous treatment
Treatment-experienced patients may need re-treatment
because of the lack of response, treatment breakthrough, un-
sustained viral response, or recurrence. Resistance to DAAs
may be genotype-related, or due to nonstructural protein
mutation. The latter is minimized by the use of drug
combinations.Since there is no ideal combination for drug-resistant HCV
infection, it may be a better choice to wait for the emergence of
new drugs or protocols in patients who are in dear need for
urgent treatment [96].
In general terms, patients who have been initially treated by
interferon and ribavirin are eligible for any of the selected
DAA combinations. Those who fail with a sofosbuvir-based
treatment may benefit from the Viekera family, and vice versa
[92].
Co-morbidity
It is important to detect viral co-infection, particularly with
HIV and HBV since both are associated with accelerated hep-
atic fibrosis. The treatment of HCV/HIV co-infection has been
addressed in the ALLY-2 trial that showed 97% SVR12 fol-
lowing treatment with a fixed dose Sofosbuvir (400 mg/day)
and a variable dose of Daclatasvir depending on the concomi-
tant administration of anti-retroviral drugs. The standard dose
is 60 mg/day, to be increased to 90 mg/day with efavirenz and
nevirapine or to 30 mg/day with ritonavir-boosted protease
inhibitors (e.g. the Viekera family) [97]. Other options are dis-
cussed in the recent AASLD guidelines [96]. It is noteworthy
that Ribavirin is contraindicated in patients receiving the
antiretroviral nucleoside analogue, didanosine, owing to the
risk of mitochondrial toxicity, which leads to hepatomegaly
and steatosis, pancreatitis, and lactic acidosis [98].
HBV-HCV co-infection constitutes a significant clinical
challenge. Liver injury, including the risk of hepatocellular car-
cinoma, is augmented, even in serologically silent HBV infec-
tion (positive antibody, negative DNA). The expression of
Interferon receptors is downregulated, hence the poor response
to such treatment. While active HBV infection suppresses
HCV replication, the extent of liver damage is even more
aggressive [99]. Little is published on the renal pathology asso-
ciated with this co-infection, yet patients on regular dialysis
Table 2 Direct Antiviral Agents currently approved for clinical use.
ID VNSP target Daily dose Combin ions
Sofosbuvir 400 mg Ribavirina Peg-Interferonb
A2 EAS (GT-4)
A4 Sofosbuvir NS5B 400 mg NEUTRINO (GT-1, GT-4), (FDA approved)
B1 Ledisprevir NS5A 90 mg ION (GT-1)-(FDA approved) NAID SYNERGY (GT-4
B2 ION (GT-1) (FDA approved) – SOLAR-2 (GT-4)
C1 OPTIMIST (GT-1) (FDA approved)
C2 Simeprevir NS3 150 mg COSMOS (GT-1)
C4 QUEST studies [FDA approved (GT-1)]
D1 Study AI444040 (GT1,2,3,4) FDA-approved GT-1,GT-3
D2 Daclatasvir NS5A 60 mg EMCUPc (GT1,2,3,4)-ALLY-1 (GT-1)d
D4 COMMAND-4
Paritaprevir NS3 150 mg
E1e Ritonavir CY450 100 mg PEARL-1 (GT4) , RUBY-1 (GT1)
Ombitasvir NS5A 25 mg (FDA approved)
Paritaprevir NS3 150 mg
E2e Ritonavir CY450 100 mg PEARL-1 (GT4), RUBY-1 (GT1)
Ombitasvir NS5A 25 mg (FDA approved)
F1 Grazoprevir NS3/4A 100 mg C-EDGE, C-SURFER (GT-1,4)
Elbasvir NS5A 50 mg (FDA approved)
F2 Grazoprevir NS3/4A 100 mg C-EDGE, C-SURFER (GT-1,4)
Elbasvir NS5A 50 mg (FDA approved)
a Weight-based dosage: 1000 mg [<75 kg] to 1200 mg [>75 kg]).
b Alpha 2A (180 mcg) or Alpha 2B (1.5 mcg/kg).
c European Multicenter Compassionate Use Program.
d Fixed Ribavirin dose of 600 mg.
e Dasabuvir (NS5B) added for GT-1. VNSP: Viral Nonstructural Protein; EAS: Egyptian Ancestry Study.
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Fig. 11 Proposed algorithm for DAA therapy in patients at different stages of CKD according to the extent of liver injury. From El-
Fishawi et al. [92].
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mortality. The risk depends on the dominant virus, being
greater when HBV dominates. Treatment should receive top
priority, combining oral drugs rather than interferon-based
protocols, addressing both viruses simultaneously.
It is important to note that HCV +ve patients may be
receiving treatment for other medical conditions. This has to
be taken into consideration while prescribing DAAs in order
to avoid drug-drug interaction than can be fatal.
Drug-drug interaction
Most of the DAAs are metabolized by the Cytochrome-P450
(CYP-450) in the liver and intestinal wall. Since this systemis also involved in the metabolism of many other drugs includ-
ing anticoagulants, statins, amiodarone, beta blockers, calcium
channel blockers, several immunosuppressive agents and
antibiotics, and many others [100], modification of CYP-450
activity by enzyme induction or inhibition can lead to critical
changes in the relevant drug levels. In order to avoid such
potentially serious complications, it is recommended to check
for drug-drug interactions using an automated tool.
Underlying cause of CKD
It is renal function, not the renal pathology or the HCV causal
role in its pathogenesis, that counts in the selection of treat-
ment protocol. Antiviral treatment in HCV-associated diabetic
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mesangiocapillary glomerulonephritis – unless the latter is
cryoglobulinemic.
Since high-grade cryoglobulinemic vasculitis can lead to
irreversible organ damage, it is recommended to control florid
vasculitic manifestations without delay, even prior to institu-
tion of anti-viral treatment. Corticosteroids and other
immunosuppressive agents [2] should be followed by a DAA,
selected according to the criteria described in this review.
Kidney function
The kidneys are responsible for the elimination of only 1–13%
of an administered dose of different DAAs, which leads to neg-
ligible retention with mild or moderate renal insufficiency. It
has been determined that no dose adjustment is required with
eGFR> 30 mL/min/1.73 sqm [101].
There is paucity of clinical trials on patients with
eGFR< 30 mL/min/1.73 sqm (Stages IV-V CKD). Given
the known risk of hemolysis with ribavirin and that of further
deterioration of kidney function with full-dose sofosbuvir,
these two agents must be avoided in their usual doses. The
manufacturer of Ledisprevir/Sofosbuvir combination protocol
(Harvoni) does not recommend its use with impaired kidney
function owing to the lack of data [102].
On the other hand, the RUBY-1 trial, which is dedicated to
patients with severe renal insufficiency, has shown 100% SVR-
12 with the Viekera-pack (comprising paritaprevir/ritonavir
+ ombitasvir + dasabuvir), with or without ribavirin [85].
Although the study was conducted on patients infected with
GT-1, it proves the concept of safety and efficacy with
eGFR< 30 ml/min/1.73sqm, which extrapolates to other
genotypes [5].
Another study has shown a SVR-12 in 13/15 patients with
severe renal insufficiency with the use of simeprevir plus half-
dose (200 mg) sofosbuvir for 12 weeks [86]. This interesting
approach has not yet been verified in a larger sample.
Daclatasvir is a promising drug for use in patients with
impaired renal function. While it is FDA-approved only for
genotypes 3 and 1, it was shown to be effective in other geno-
types including GT-4, when combined with Sofosbuvir and
Ribavirin (e.g. Multicenter Compassionate Use Program
[94]), or peg-interferon (COMMAND-4 study [103]. There
are no clinical data on the use of Daclatasvir in patients with
impaired renal function. However, a well-controlled study
(AI444-063) of the pharmacokinetics of Daclatasvir has shown
a favorable profile, even in patients with severe renal failure.
The blood levels were slightly increased, yet within the desir-
able therapeutic range [104].
The recently FDA-approved Grazoprevir + Elbasvir com-
bination (Zepatier) has shown remarkable efficacy as well as
safety in Stages IV and V CKD, including treatment-naive as
well as treatment-experienced GT-1 infected patients. In the
seminal C-SURFER study, the overall SVR12 rate in such
patients was 99% [105].
Dialysis
In addition to the constraints of using DAAs in CKD Stages
IV/V, drug analyzability is an additional factor to consider
upon selecting suitable treatment for patients on regular dial-ysis. Dialyzability depends on the drug’s molecular size and
configuration, its protein binding, electrostatic charge and
other less significant factors. It is possible to predict drug dia-
lyzability by physical and pharmacokinetic studies, yet clinical
trials remain crucial for a final conclusion.
An example of the complexity of this issue is sofosbuvir
[106]. It has a relatively small molecular size that permits rapid
diffusion through standard dialysis membranes. However, it is
61% protein bound, which checks its efflux. It is neutral mole-
cule, which is activated by phosphorylation that renders it neg-
atively charged, which repels it from the dialysis membrane.
According to these opposing factors, it is imperative to design
dedicated RCTs for all DAAs that can be used for patients on
RDT.
Until such data is available, the only evidence-based recom-
mendations would be the Viekera family [85] (without Dasabu-
vir in GT-4 according to the PEARL-1 study [107]), the
Grazoprevir plus elbasvir combination in GT-1 [105] and, less
confidently, the Simeprevir + 1/2 dose Sofosbuvir [86], which
have yielded SVR-12 of 100%, 99% and 84.6% respectively,
following 12-week treatment.
Post-transplant
Two factors must be considered while selecting antiviral treat-
ment after kidney transplantation: graft function and drug
pharmacokinetics. All rules regarding graft function in native
kidneys apply to the contemporary post-transplant eGFR.
Drug pharmacokinetics is a compelling factor when cyclos-
porine, tacrolimus, sirolimus or everolimus is used for
immunosuppression. All these agents are metabolized by
CYP-450, for which most DAAs compete. This generally
requires full dose treatment with DAAs and modification of
immunosuppressive drug doses according to blood levels. Clin-
ical experience has shown considerable variation in the
required dose adjustments. For example, simeprevir/cy-
closporine interaction is so clinically relevant that it is recom-
mended to avoid this combination all together (EASL-B1)
[101]. Simeprevir may be used with Tacrolimus or Sirolimus,
yet with frequent monitoring of their blood levels. No dose
adjustment is required for tacrolimus or cyclosporine use with
sofosbuvir plus ribavirin, ledipasvir or daclatasvir (EASL-A2)
[101].
The Viekera family is the riskiest in this context, owing to
its essential component ritonavir that is meant to inhibit
CYP-450 in order to sustain a therapeutic blood level of
another component, paritaprevir. Using this combination
requires avoidance of mTOR inhibitors all together, dose
reduction of Tacrolimus to 0.5 mg weekly and Cyclosporine
to one-fifth its dose (EASL-A2) [101]. Avoiding Viekera does
not pause a significant challenge if the eGFR is above 30 ml/
min/1.73 sqm, owing to the availability of other alternatives.
Below this level, the choice becomes limited to either Simepre-
vir + 1/2 dose sofosbuvir on the basis of a small study, or
Daclatasvir/Sofosbuvir on the basis of favorable pharmacoki-
netics [104].
Conclusions
HCV is far from being an innocent by-stander in patients with
kidney disease. As explained in this review, it constitutes a
Hepatitis C and kidney disease 127major risk to patients’ lives at all stages of their illness. Since
the damage is irreversible without treatment, every patient
must be seen as a candidate for treatment. For logistic reasons,
though, the lack of resources may impose treatment prioritiza-
tion to those with highest expectation from treatment. Fortu-
nately, with the recent discovery of safe and highly effective
directly acting antiviral drugs, there are multiple therapeutic
options that can suit different patients, taking many confound-
ing factors into consideration. These include the CKD stage,
extent of liver disease, viral strain, co-infections, previous
treatment experience, current comorbidity and concomitant
medical treatment. With adequate choice of a suitable proto-
col, cure rates over 90% are expected in most patients, with
highly positive impact on survival and quality of life.
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